ZYUS Life Sciences has formed a partnership with a University of Saskatchewan research team to begin the process with pre-trial study
.
The 18-month study will establish a baseline foundation for clinical trials.
ZYUS President C-E-O Brent Zettl says the entire process could take about five years with the hope of developing a fixed-dose combination.
Zettl says their goal is doctor-prescribed capsules that could treat disorders like depression, anxiety and post-traumatic stress disorder without side-effects.
The head of the company focused on producing medically based cannabis products feels it’s just as important to prevent symptoms that could have a negative impact on the patient’s quality of life.
Zettl says the medical cannabis industry has taken off since 2014 when the federal government expanded the number of conditions that could be treated with cannabis oils and products to 168.
